Ocular Therapeutix Inc [OCUL] stock is trading at $11.96, up 3.55%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OCUL shares have gain 6.31% over the last week, with a monthly amount glided 42.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $17. On March 11, 2025, Needham initiated with a Buy rating and assigned a price target of $15 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. TD Cowen upgraded its rating to a Buy and raised its price target to $11 on June 20, 2024. In a note dated February 09, 2024, BofA Securities initiated an Buy rating and provided a target price of $15 on this stock.
Ocular Therapeutix Inc [OCUL] stock has fluctuated between $5.78 and $11.77 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $11.96 at the most recent close of the market. An investor can expect a potential return of 58.86% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 59.65M for the trailing twelve months, which represents a drop of -27.59%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -3.23%, and Net Profit Margin reading is -3.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.59 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.70 points at the first support level, and at 11.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.09, and for the 2nd resistance point, it is at 12.22.
Ratios To Look Out For
For context, Ocular Therapeutix Inc’s Current Ratio is 10.22. Further, the Quick Ratio stands at 10.14, while the Cash Ratio is 9.22. Considering the valuation of this stock, the price to sales ratio is 31.94, the price to book ratio is 7.16.
Transactions by insiders
Recent insider trading involved Waheed Nadia, Chief Medical Officer, that happened on Jun 02 ’25 when 13861.0 shares were sold. Officer, NADIA K. WAHEED completed a deal on Jun 02 ’25 to buy 13861.0 shares. Meanwhile, Chief Strategy Officer Nayak Sanjay sold 1862.0 shares on May 23 ’25.
